Skip to main content
Premium Trial:

Request an Annual Quote

FDA to use Ingenuity Pathways Analysis for Review of Pharmacogenomics Data

NEW YORK, June 21 (GenomeWeb News) - Ingenuity said today that the US Food and Drug Administration has licensed its Ingenuity Pathways Analysis platform for use in the review of pharmacogenomics data submissions. 

 

The FDA and Ingenuity will collaborate on merging Ingenuity's data and software suite with the FDA's ArrayTrack informatics system using a new integration module in Ingenuity Pathways Analysis.

 

ArrayTrack, a microarray data-management and -analysis system, was developed by the FDA's Center for Toxicoinformatics at the NationalCenter for Toxicological Research (NCTR). Further details of the system are available here.

 

Last August, the FDA integrated another pathway database, PathArt from Jubilant Biosys, into ArrayTrack.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.